IL17A and ischemic stroke: Consistently, previous results also suggest that the over expression of IL-17 indicates a poorer treatment effect and prognosis for ischemic stroke (He et al., 2019; Tian et al., 2019; Zhou et al., 2019), which always abolishes some neuroprotective effect (Ma et al., 2018; Sun et al., 2018; Zhao et al., 2019) and it can be reduced by As IV (Jin et al., 2017; Zhang et al., 2018).